Drug intelligence / Profile preview

bevacizumab + carboplatin + fosbretabulin + paclitaxel

Development stage: Unknown
Lead developer: Oncotelic Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

A combination therapy consisting of bevacizumab, carboplatin, fosbretabulin, and paclitaxel. Bevacizumab is an antibody that works by decreasing blood supply to tumors. Carboplatin is a platinum-containing compound that attacks fast-growing cancer cells. Paclitaxel is a chemotherapy agent that disrupts cell division. Fosbretabulin (combretastatin A4 phosphate) is a vascular disrupting agent. This combination may be used in the treatment of various cancers.

Brand names: Avastin
Other names: BCP plus fosbretabulin tromethamine

Targets

TUBB (Tubulin (alpha and beta subunits))VEGFA (Vascular endothelial growth factor A)DNA

Beyond the preview

Go deeper on bevacizumab + carboplatin + fosbretabulin + paclitaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bevacizumab + carboplatin + fosbretabulin + paclitaxel.

Explore the full profile